Teva Gambles Indictment Is Better Than Pleading Guilty To Price-Fixing Claims
Executive Summary
Teva’s market overhang and legal uncertainty intensifies with DOJ charges it conspired to fix generic drug prices. Five other companies have pled guilty and reached deferred prosecution agreements.
You may also be interested in...
Divided FTC Okays Mylan-Upjohn Merger But Election Outcome Could Impede Future Deals
Commissioners vote 3-2 that Mylan and Pfizer’s Upjohn can combine after divesting seven products; dissenting votes focus on price fixing allegations as commissioners Chopra and Slaughter criticize majority for not addressing government’s case against Pfizer and Mylan. Former FTC attorneys note that if Biden wins the presidential election, he could nominate one of the dissenters to FTC chair and give more traction to their views.
Teva Is Latest To Be Hit With DOJ Suit Over Charity Copays
Government claims Teva’s payments to two foundations to cover Copaxone copays violated Anti-Kickback statute. Teva is bucking settlement trend in DOJ’s industrywide investigation of sponsor ties to charitable foundations.
Teva Chosen As 'Bellwether' In US Price-Fixing Litigation
Litigation involving Teva has been selected as a “bellwether” case, making it a priority for trial as part of the ongoing US investigation into generic price-fixing.